Homepage
Author:
Kymera Therapeutics, Inc.
Posted Date:
April 13, 2026
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
Kymera Therapeutics, Inc.
April 13, 2026
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
Kymera Therapeutics, Inc.
April 9, 2026
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Kymera Therapeutics, Inc.
March 28, 2026
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Kymera Therapeutics, Inc.
March 10, 2026
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Kymera Therapeutics, Inc.
February 24, 2026
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Kymera Therapeutics, Inc.
February 19, 2026
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
Kymera Therapeutics, Inc.
February 4, 2026
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics, Inc.
January 29, 2026
